Clinical trials: Treatment Resistant Depressive Disorder
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Depressive Disorder, Major
Abilify as an Adjunctive Treatment for Refractory Depression
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not…
- Trial name
- NCT00220636
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Treatment-Resistant Depression, Bipolar Depression
Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression
The goal of this clinical trial is to evaluate the safety and initial effectiveness of MR-guided focused ultrasound (MRgFUS) bilateral capsulotomy in patients with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT07108257
- Testing
- ExAblate Neuro 4000
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment-resistant Depression (TRD), Major Depression Disorder
Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression
The primary objective of this study is to evaluate the clinical efficacy of moderate-dose transcranial photobiomodulation (t-PBM) at different frequencies (10 Hz and 40 Hz) in patients with treatment-resistant depression (TRD).
- Trial name
- NCT07543328
- Testing
- transcranial photobiomodulation
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Depression
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
- Trial name
- NCT03870776
- Testing
- MAP4343
- Where
- 10 sites in France
- Volunteers
- 126 people
- Sponsor
- Mapreg
Treatment Resistant Depression
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression
The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD).
- Trial name
- TREK (NCT06278779)
- Testing
- Esketamine group, Racemic ketamine
- Where
- 7 sites in Australia
- Volunteers
- 162 people
- Sponsor
- The George Institute
Unipolar Major Depression
Theta Burst Study Ghent
50 Right-handed antidepressant-free unipolar depressed patients (age 18-65 years) will be treated with in total 20 Theta burst sessions; these will be spread over 4 days.
- Trial name
- TBS Ghent (NCT01832805)
- Testing
- Theta burst stimulation.
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Ghent
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depression, Anxiety Disorders
Cognitive and Drug Therapy for Drug-Resistant Depression
To develop an effective combined cognitive therapy (CT) plus drug treatment for patients with drug-resistant depression (DRD) (i.e., depression that is refractory to medication).
- Conditions
- Depression, Anxiety Disorders, Personality Disorders, Drug-resistant Depression
- Trial name
- NCT00000376
- Testing
- Cognitive therapy, Desipramine
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression
Transcranial direct current stimulation (tDCS) is a noninvasive method to activate or de-activate neurons in superficial regions of the brain through the induction of weak electric currents in the brain tissue delivered by two…
- Trial name
- NCT01450150
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Douglas Mental Health University Institute
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Treatment Resistant Depression
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
- Trial name
- NCT04433858
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sheppard Pratt Health System
Treatment Resistant Depression
Neural and Antidepressant Effects of Propofol
This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.
- Trial name
- NCT03684447
- Testing
- Propofol
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Utah
Depression, Depressive Disorder, Major
Comparing the Efficacy of Accelerated vs. Standard fMRI-guided iTBS in Treating Adolescents Depression
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and…
- Trial name
- NCT06528938
- Testing
- Theta Burst Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Depressive Disorder, Major
Peripheral Immunomarker Validation in Treatment-resistant Depression
This is a study to characterise the role of inflammatory processes in depression. There is compelling evidence that inflammation is often associated with, and can cause, depression.
- Trial name
- BIODEP (NCT02752178)
- Testing
- MA, DEP
- Where
- 5 sites in United Kingdom
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Treatment Resistant Depression
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
To determine the effect of ketamine, compared to propofol, when used an an anesthetic agent for electroconvulsive therapy (ECT) in the treatment of major depressive disorder (MDD).
- Trial name
- NCT01935115
- Testing
- Propofol, Ketamine
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of Saskatchewan
Major Depressive Disorder
Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)
The aim of this randomized multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression.
- Trial name
- Early-TMS (NCT06545474)
- Testing
- bilateral theta burst stimulation, SSRI treatment
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen